Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mohamed Hamouda, Mohamed Farghaly & Sara Al Dallal. (2023) Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation. ClinicoEconomics and Outcomes Research 15, pages 549-558.
Read now
Read now
Soichiro Hozawa, Hiroyuki Ohbayashi, Michiko Tsuchiya, Yu Hara, Laurie A Lee, Takashi Nakayama, Jun Tamaoki, Andrew Fowler & Takanobu Nishi. (2021) Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study. Journal of Asthma and Allergy 14, pages 809-819.
Read now
Read now
Yoichi Nakamura, Soichiro Hozawa, Hironori Sagara, Hiroyuki Ohbayashi, Laurie A. Lee, Jodie Crawford, Jun Tamaoki, Takanobu Nishi & Andrew Fowler. (2021) Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Current Medical Research and Opinion 37:9, pages 1657-1665.
Read now
Read now
Akira Umeda, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada & Koich Fukunaga. (2019) Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma. Cogent Medicine 6:1.
Read now
Read now
Edward Kerwin, Neil Barnes, Michael Gibbs, David Leather, Richard Forth, Loretta Jacques & Louisa J. Yates. (2018) Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials. Journal of Asthma 55:8, pages 890-897.
Read now
Read now
Timothy E Albertson, Samuel W Bullick, Michael Schivo & Mark E Sutter. (2016) Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Design, Development and Therapy 10, pages 4047-4060.
Read now
Read now
Emma L. Gray, Vicky Chang & Paul S. Thomas. (2016) Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma. Expert Review of Respiratory Medicine 10:8, pages 839-847.
Read now
Read now
Articles from other publishers (25)
Yuji Oba, Sumayya Anwer, Tarang Patel, Tinashe Maduke & Sofia Dias. (2023) Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2023:8.
Crossref
Crossref
. (2023) Entzündungskontrolle auch in der Bedarfstherapie. Pneumo News 15:2, pages 57-57.
Crossref
Crossref
Yuji Oba, Sumayya Anwer, Tinashe Maduke, Tarang Patel & Sofia Dias. (2022) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2022:12.
Crossref
Crossref
Roberto W. Dal Negro & Paola Turco. (2022) Effects of Adherence to Once-Daily Treatment on Lung Function, Bronchial Hyperreactivity and Health Outcomes in Adolescents with Mild-to-Moderate Asthmoka: A Twelve-Month Survey. Children 9:12, pages 1854.
Crossref
Crossref
O. V. Fesenko. (2022) Bronchial asthma: focus on adherence to inhaled therapy. Meditsinskiy sovet = Medical Council 16:18, pages 40-48.
Crossref
Crossref
Raja Dhar, Deepak Talwar, Prince James, Ashwini Mishra, Judo Vachaparambil, Saiprasad Patil, Nishtha Khatri, Sagar Bhagat & Hanmant Barkate. (2022) ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts. Advances in Respiratory Medicine 90:5, pages 407-424.
Crossref
Crossref
V. V. Naumova, E. K. Beltyukov, V. Ch. Abdullaev & E. V. Shevtseva. (2022) The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice. Meditsinskiy sovet = Medical Council:4, pages 8-14.
Crossref
Crossref
Miriam Barrecheguren, Monica Monteagudo, Marc Miravitlles, Xavier Flor, Alexa Núñez, Jeisson Osorio, Xavier Muñoz & Iñigo Ojanguren. (2022) Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain. npj Primary Care Respiratory Medicine 32:1.
Crossref
Crossref
John Oppenheimer, Michael Bogart, Lindsay G.S. Bengtson, John White, Kevin Sundquist, Robson Lima & Carlyne Averell. (2022) Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in Asthma. The Journal of Allergy and Clinical Immunology: In Practice 10:2, pages 485-494.e5.
Crossref
Crossref
A. A. Viesel & I. Yu. Viesel. (2022) Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review. Meditsinskiy sovet = Medical Council:21-1, pages 72-78.
Crossref
Crossref
Alexandrosz Czira, Monica Turner, Amber Martin, David Hinds, Helen Birch, Frances Gardiner & Shiyuan Zhang. (2022) A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respiratory Medicine 191, pages 106670.
Crossref
Crossref
Shuying Yang, Laurie A. Lee, Neal Sule, Andrew Fowler & Guy Peachey. (2021) Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical Pharmacokinetics 60:7, pages 887-896.
Crossref
Crossref
John Oppenheimer, David J. Slade, Beth A. Hahn, Laurie Zografos, Alicia Gilsenan, David Richardson, David McSorley, Robson Lima, Nestor A. Molfino & Carlyne M. Averell. (2021) Real-world evidence. Annals of Allergy, Asthma & Immunology 126:4, pages 385-393.e2.
Crossref
Crossref
Laurie A Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards, Andrew Fowler, Nicola A Hanania, Huib A M Kerstjens, Edward Kerwin, Robert Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer & Ian D Pavord. (2021) Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine 9:1, pages 69-84.
Crossref
Crossref
Durgawati Patel, Kuldeep Kumar Namdev, Kanika Verma, Ritika Gururani, Akansha Tiwari, Puspendra Kumar, Rikeshwer Prasad Dewangan, Saikh Mohammad Wabaidur, Swapnil Sharma & Jaya Dwivedi. (2019) HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. Journal of Chromatography B 1132, pages 121842.
Crossref
Crossref
Richard Beasley, James Harper, Grace Bird, Ingrid Maijers, Mark Weatherall & Ian D. Pavord. (2019) Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. American Journal of Respiratory and Critical Care Medicine 199:12, pages 1471-1477.
Crossref
Crossref
Maria Malmlöf, Mattias Nowenwik, Kristof Meelich, Iwona Rådberg, Ewa Selg, John Burns, Hermann Mascher & Per Gerde. (2019) Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs. European Journal of Pharmaceutics and Biopharmaceutics 139, pages 213-223.
Crossref
Crossref
Roberto W. Dal Negro, Luca Bonadiman & Paola Turco. (2018) Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
Henrik Svedsater, Helen A. Doll, Jake Macey, Gail Miles, Lisa Bradshaw & Magdalena Vanya. (2018) Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences. Advances in Therapy 35:9, pages 1378-1399.
Crossref
Crossref
Roberto W. Dal Negro, Luca Bonadiman & Paola Turco. (2018) Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma. Therapeutic Advances in Respiratory Disease 12, pages 175346661878989.
Crossref
Crossref
Emma D. Deeks, Katherine A. Lyseng-Williamson & Yahiya Y. Syed. (2017) Fluticasone furoate/vilanterol dry-powder inhaler in asthma: a guide to its use in the EU. Drugs & Therapy Perspectives 33:4, pages 153-159.
Crossref
Crossref
Roberto W. Dal Negro, Chiara Distante, Luca Bonadiman, Paola Turco & Sergio Iannazzo. (2016) Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Gustavo J. Rodrigo & Vicente Plaza. (2016) Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma. Annals of Allergy, Asthma & Immunology 116:6, pages 565-570.
Crossref
Crossref
William W. Busse, Leslie Andersen, Lucy Frith, Catherine Harvey & Loretta Jacques. (2016) An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies. Pulmonary Therapy 2:1, pages 91-114.
Crossref
Crossref
E V Nazarova & E A Latysheva. (2015) Relvar Ellipta® - new molecule in a new delivery system - new horizons in the treatment of bronchial asthma. Russian Journal of Allergy 12:5, pages 82-89.
Crossref
Crossref